Penumbra(PEN.US) Director Sells US$3.58 Million in Common Stock
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
3 Reasons Growth Investors Will Love Penumbra (PEN)
Penumbra Inc. Earnings Call Highlights Strong U.S. Growth
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $315 to $330
Penumbra First Quarter 2025 Earnings: Beats Expectations
Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating
12 Health Care Stocks Moving In Thursday's After-Market Session
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
Penumbra Is Maintained at Outperform by RBC Capital
Express News | RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $330
Penumbra Is Maintained at Buy by UBS
Penumbra Price Target Raised to $330.00/Share From $315.00 by Truist Securities
Penumbra Is Maintained at Buy by Stifel
Stifel Maintains Buy on Penumbra, Raises Price Target to $318
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
UBS Adjusts Price Target on Penumbra to $330 From $320, Maintains Buy Rating
New Analyst Forecast: $PEN Given $318.0 Price Target
Penumbra Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results. Additionally, Baird and Wells Fargo Raised Their Respective Price Targets on the Stock.
Express News | Penumbra Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results. Additionally, Baird and Wells Fargo Raised Their Respective Price Targets on the Stock